Paul Matteis

Latest articles

4d
Boston Globe
Sage Therapeutics stock soars 70% on rosy drug-test datahad achieved remission, compared to 33 percent of placebo patients — not statis
Boston Globe / Posted 4 days ago
had achieved remission, compared to 33 percent of placebo patients — not statistically significant. Leerink analyst Paul Matteis said that using a 14-day end-point is shorter than typical depression drug studies, but any amount of off-drug... Read more
4 related articles

In this news